8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
May 1, 2026·SEC
Material company update
Apr 28, 2026·SEC
Drugs Made In America Acquisition Corp. Ordinary Shares(DMAA)Earnings, Financials & Key Ratios
DMAA•NASDAQ
$10.66
56.1× P/E·Price updated Jul 7, 2026
SectorFinancial ServicesIndustrySPACs & Shell CompaniesSub-IndustryHealthcare and life sciences SPACs
AboutDrugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.Show more
- EBITDA-$3M-281601400.0%
- Net Income$6M+1240317.7%
- EPS (Diluted)0.19+439.3%
- ROE5.11%
DMAA Price & Volume
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) stock price & volume — 10-year historical chart
Loading chart...
Terminal Shell Entity Faces Critical Liquidity Constraints
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Insolvency and liquidation risk
Key Thesis Takeaways
- Drugs Made In America Acquisition Corp.
- functions as a pre-combination shell entity with zero operational revenue and a history of non-operating accounting adjustments that distort its true financial health.
- The company faces severe insolvency risks as its cash reserves have dwindled to a nominal $14,900 as of 2026Q1, leaving it unable to sustain its administrative burn rate.
- Investors should exercise extreme caution, as the entity lacks the tangible capital required to execute a viable business combination without significant shareholder dilution.
Verdict Logic
the company's current ratio of 0.03 and the depletion of cash reserves to $14,900 indicate an imminent risk of insolvency and an inability to maintain its public listing status.
DMAA Growth Metrics
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM500.08%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-99.58%
Return on Capital
10 Years-2.35%
5 Years-2.35%
3 Years-2.35%
Last Year-2.35%
Peers Comparison
Key metrics vs top competitors for Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.66 | $359.42M | 56.11 | — | — | 5.11% | — | |
| $8.55 | $9.62M | -0.23 | -83.94% | — | — | — | |
| $0.37 | $3.35M | -0.24 | -10.3% | -3089.55% | -423.84% | — | |
| $5.67 | $1.97B | -9.45 | 698.96% | -102.06% | -44.1% | — | |
| $128.86 | $318.26B | 17.70 | 1.18% | 13.62% | 17.91% | — | |
| $24.07 | $136.92B | 17.70 | -1.65% | 11.83% | 8.34% | — |
Compare DMAA vs Peers
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DMAA SEC Filings & Documents
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when DMAA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DMAA Frequently Asked Questions
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is DMAA profitable?
Yes, Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) is profitable, generating $6.7M in net income for fiscal year 2025.
Dividend & Returns
What is DMAA's return on equity?
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has a return on equity (ROE) of 5.1%. This is below average, suggesting room for improvement.
What is Drugs Made In America Acquisition Corp. Ordinary Shares's free cash flow?
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) had negative free cash flow of $0.4M in fiscal year 2025, likely due to heavy capital investments.